Nephro Care India Limited Stock Price Today (NSE: NEPHROCARE)
Fundamental Score
Nephro Care India Limited Share Price Live NSE/BSE & Institutional Fundamental Analysis
Nephro Care India Limited share price today is ₹79.50, up +0.00% on NSE/BSE as of 17 February 2026. Nephro Care India Limited (NEPHROCARE) is a Small-cap company in the Hospital sector with a market capitalisation of ₹220.67 (Cr). The 52-week high for NEPHROCARE share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 65.09x, NEPHROCARE is currently trading above its industry average P/E of 52.84x. The company has a Return on Equity (ROE) of 8.38% and a debt-to-equity ratio of 0.00.
Nephro Care India Limited Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Nephro Care India Limited Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Nephro Care Share Price: A Conservative Investor's Perspective
Hospitals, unlike many businesses, benefit from relatively inelastic demand; people need healthcare regardless of economic conditions. However, navigating the nuances of operational efficiency and regulatory landscapes is crucial for sustained profitability. This analysis examines the Nephro Care share price through the lens of a conservative value investor prioritizing capital preservation. Currently trading at ₹101.0, with a PE ratio of 65.09, Nephro Care India Limited warrants careful scrutiny regarding its valuation relative to its performance.
One immediate concern is the elevated PE ratio. A PE of 65.09 suggests that the market has high growth expectations baked into the Nephro Care share price. Whether those expectations are realistically achievable requires deeper investigation into their growth strategy, competitive landscape, and financial health. Comparing Nephro Care with its peers, such as
Strategic Minerals Plc, highlights the need to assess management quality and capital allocation decisions. While Strategic Minerals Plc may operate in a different sector, analyzing their historical performance under similar economic conditions can provide insights into the capabilities of Nephro Care's leadership.The Return on Capital Employed (ROCE) of 11.27% is a critical metric. While positive, it is essential to determine if this level of return is sufficient to create a sustainable competitive advantage, or "moat." A higher ROCE, consistently maintained, signals efficient capital utilization and pricing power. A lower ROCE, conversely, suggests vulnerability to competition and potentially shrinking margins. Sustaining and improving this ROCE is vital for Nephro Care to justify its current valuation and generate shareholder value over the long term.
Ultimately, a conservative investment decision requires a holistic understanding of Nephro Care's financial statements, management track record, and the broader healthcare sector dynamics. This analysis is part of a larger 80-parameter fundamental audit, verified by Sweta Mishra, designed to provide a comprehensive and objective assessment of the company's investmentworthiness. The analysis remains observational and does not constitute investment advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Nephro Care India Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of NEPHROCARE across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Operating Margins (16.80%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Strong Revenue Growth (122.33%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (143.29% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (16.80% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (210.58% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (26.61x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (61.47%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Below-Average Return on Equity (8.38%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Premium Valuation Risk (P/E: 65.09x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-11.42%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Negative Free Cash Flow (₹-22.86 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 4.51%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Nephro Care India Limited Financial Statements
Comprehensive financial data for Nephro Care India Limited including income statement, balance sheet and cash flow
About NEPHROCARE (Nephro Care India Limited)
Nephro Care India Limited (NEPHROCARE) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Hospital sector with a current market capitalisation of ₹220.67 (Cr). Nephro Care India Limited has delivered a Return on Equity (ROE) of 8.38% and a ROCE of 11.27%. The debt-to-equity ratio stands at 0.00, reflecting the company's capital structure. Investors tracking NEPHROCARE share price can monitor key metrics including P/E ratio, promoter holding of 61.47%, and quarterly earnings growth.
Company Details
NEPHROCARE Share Price: Frequently Asked Questions
What is the current share price of Nephro Care India Limited (NEPHROCARE)?
As of 17 Feb 2026, 10:17 am IST, Nephro Care India Limited share price is ₹79.50. The NEPHROCARE stock has a market capitalisation of ₹220.67 (Cr) on NSE/BSE.
Is NEPHROCARE share price Overvalued or Undervalued?
NEPHROCARE share price is currently trading at a P/E ratio of 65.09x, compared to the industry average of 52.84x. Based on this relative valuation, the Nephro Care India Limited stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of NEPHROCARE share price?
The 52-week high of NEPHROCARE share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Nephro Care India Limited share price?
Key factors influencing NEPHROCARE share price include quarterly earnings growth (Sales Growth: 122.33%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Nephro Care India Limited a good stock for long-term investment?
Nephro Care India Limited shows a 5-year Profit Growth of 210.58% and an ROE of 8.38%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing in NEPHROCARE shares.
How does Nephro Care India Limited compare with its industry peers?
Nephro Care India Limited competes with major peers in the Hospital. Investors should compare NEPHROCARE share price P/E of 65.09x and ROE of 8.38% against the industry averages to determine competitive standing.
What is the P/E ratio of NEPHROCARE and what does it mean?
NEPHROCARE share price has a P/E ratio of 65.09x compared to the industry average of 52.84x. Investors pay ₹65 for every ₹1 of annual earnings.
How is NEPHROCARE performing according to Bull Run's analysis?
NEPHROCARE has a Bull Run fundamental score of 57.1/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does NEPHROCARE belong to?
NEPHROCARE operates in the Hospital industry. This classification helps understand the competitive landscape and sector-specific trends affecting Nephro Care India Limited share price.
What is Return on Equity (ROE) and why is it important for NEPHROCARE?
NEPHROCARE has an ROE of 8.38%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Nephro Care India Limited generates profits from shareholders capital.
How is NEPHROCARE debt-to-equity ratio and what does it indicate?
NEPHROCARE has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk.
What is NEPHROCARE dividend yield and is it a good dividend stock?
NEPHROCARE offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Nephro Care India Limited shares.
How has NEPHROCARE share price grown over the past 5 years?
NEPHROCARE has achieved 5-year growth rates of: Sales Growth 143.29%, Profit Growth 210.58%, and EPS Growth 16.80%.
What is the promoter holding in NEPHROCARE and why does it matter?
Promoters hold 61.47% of NEPHROCARE shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Nephro Care India Limited.
What is NEPHROCARE market capitalisation category?
NEPHROCARE has a market capitalisation of ₹221 crores, placing it in the Small-cap category.
How volatile is NEPHROCARE stock?
NEPHROCARE has a beta of N/A. A beta > 1 suggests the Nephro Care India Limited stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is NEPHROCARE operating profit margin trend?
NEPHROCARE has a 5-year average Operating Profit Margin (OPM) of 16.80%, indicating the company's operational efficiency.
How is NEPHROCARE quarterly performance?
Recent quarterly performance shows Nephro Care India Limited YoY Sales Growth of 122.33% and YoY Profit Growth of -11.42%.
What is the institutional holding pattern in NEPHROCARE?
NEPHROCARE has FII holding of 3.47% and DII holding of 1.04%. Significant institutional holding often suggests professional confidence in the Nephro Care India Limited stock.